

Seasonal Respiratory Products Order Form for Hospitals, Physicians, Primary Care and Midwives

Mailing Address:

Niagara Region Public Health
1815 Sir Isaac Brock Way
P.O. Box 1052
Thorold, ON L2V 0A2
905-688-8248 Toll free: 1-888-505-6074 ext. 7396
niagararegion.ca/health

Complete and return this form by fax
to 905-688-4667 or email **vpd@niagararegion.ca**

Order No:

Program assistant
initials:

All vaccine orders require:

- A copy of your current 4 week fridge temperature log (up to present day)
- 3 full business days prior to scheduled delivery date to fill the order.

Vaccine Ordering Reminders Memo (createsend.com/t/t-ADD230E9005EDBC22540EF23F30FEDED)

Facility name:

Phone:

Ext:

Contact:

Date (mm/dd/yyyy):

Email:

Important reminders:

- All vaccine orders will be delivered to your facility according to the **vaccine delivery schedule** (niagararegion.ca/health/professionals/vaccine/vaccine-schedule.aspx)
- Orders will be filled based on product availability. Do not delay COVID-19 or influenza vaccination to wait for a particular product, especially since supply may be unpredictable.
- Do not schedule or plan any large immunization clinics for the general population until you have ordered and received additional vaccine for influenza and Respiratory syncytial virus (RSV)
- Co-administration is encouraged to help mitigate the impacts of the respiratory season

COVID-19 Vaccine

Facility name:

Phone:

Ext:

A COVax account is needed to order COVID-19 vaccine. If you have an existing account, log-in prior to ordering vaccine to confirm your account is still active.

Email nrphcovaxsupport@niagararegion.ca to get a COVax account or if you need support for an existing account.

Vaccine may be moved in a frozen state from Public Health and will need to be thawed prior to administration. Never freeze COVID-19 vaccine after receiving your supply.

COVID-19 vaccine should not routinely be transported, except under exceptional circumstances based on a risk assessment, follow **Ministry of Health COVID-19 Vaccine Storage and Handling guidance** (ontario.ca/page/covid-19-vaccine-program#section-2).

Vaccines	Trade Name	Doses on hand	Doses requested
COVID-19 LP.8.1 • Children 6 months to under 5 years old	Moderna Spikevax 25 mcg/0.25 mL ¹		
COVID-19 LP.8.1 • Children 5 to 11 years old	Moderna Spikevax 25 mcg/0.25 mL ¹ or Pfizer-BioNTech Comirnaty 10 mcg/0.3 mL		
COVID-19 LP.8.1 • 12 years of age and older	Moderna Spikevax 50 mcg/0.5 mL ¹ or Pfizer-BioNTech Comirnaty 30 mcg/0.3 mL		

- Follow Ministry of Health guidance for spring 2026 COVID-19 vaccine eligibility
- Refer to Ministry of Health immunization documents at **COVID-19 Vaccine Program** (ontario.ca/page/covid-19-vaccine-program)

1 The Moderna product is the same vaccine regardless of the patient's age. This means that age-appropriate doses can be drawn up from the same multi-dose vial.

Influenza Vaccine

Facility name:

Phone:

Ext:

Vaccines	Trade Name	Doses on hand	Doses requested
Standard-dose Trivalent (TIV) • 6 months of age and older	Fluzone®, Fluviral or Flucelvax®		
High-dose Trivalent (TIV-HD) or Adjuvanted Trivalent (TIV-adj) • 65 years of age and older	Fluzone® High-dose or Fluad®		

- If a child under 9 years of age is receiving the influenza vaccine for the first time, they require 2 doses 4 weeks apart
- Refer to **Universal Influenza Immunization Program** (ontario.ca/page/universal-influenza-immunization-program)

Respiratory Syncytial Virus (RSV) Products

Facility name:

Phone:

Ext:

Vaccines	Trade Name	Doses on hand	Doses requested
Monoclonal antibody (mAb) for infants and high-risk children ²	Beyfortus® 50 mg		
Monoclonal antibody (mAb) for infants and high-risk children ²	Beyfortus® 100 mg		
Vaccine for pregnant individuals Do not administer RSV vaccine to a pregnant individual who has already received a dose of RSV vaccine during a past pregnancy.	Abrysvo®		
Vaccine for <ul style="list-style-type: none"> High-risk individuals 60 years of age and older Individuals 75 years of age and older Adults who have received a previous RSV dose are not eligible to receive another publicly funded dose this season.	Abrysvo® or Arexvy®		

- Beyfortus® is the preferred product to protect infants and high-risk children from RSV. Dosing is dependent on the age and weight of the recipient
- Administration of both Abrysvo® to the pregnant individual and Beyfortus® to the infant is not recommended except under specific circumstances
- Refer to **Ministry of Health fact sheets at Respiratory Syncytial Virus (RSV) prevention programs** (ontario.ca/page/respiratory-syncytial-virus-rsv-prevention-programs#section-3)

2 These RSV products are not available to midwives as per **O. Reg. 188/24: DESIGNATED DRUGS AND SUBSTANCES** (ontario.ca/laws/regulation/240188) for vaccines under the scope of practice (as deemed clinically appropriate until the client is discharged)